pose tissues. It is well known that leptin, the product of the ob gene, is an endocrine hormone that regulates adipose tissue mass. In addition several in vitro and in vivo studies have revealed that leptin induces MMP-2 expression and activity [7] [8] [9] [10] [11] [12] . This raises the question whether the marked effect of gelatinase inhibition by Tolylsam in a murine model of nutritionally induced obesity may be due not only to direct MMP inhibition, but also to an indirect effect via reduction of leptin and associated decrease in MMP-2 levels. Therefore, in the present study we have administered Tolylsam to leptin deficient ob/ob mice. Our data indicate that, also in the absence of leptin, MMP inhibition has the potential to impair adipose tissue development.
Material and Methods

Obesity model
Five-week old male leptin deficient (ob/ob) mice (C57Bl/6 genetic background), purchased from Charles River Laboratories (Horsham, Pennsylvania, USA) were kept in microisolation cages on a 12h day/ night cycle and fed at libitum with a high fat diet (HFD, Harlan Teklad TD 88137, Zeist, The Netherlands; 42 % Quality of collagen fibers was estimated by Sirius red polarization microscopy, allowing to quantify thick, tightly packed collagen fibers (orange-red) and thin, loosely assembled fibers (yellow-green) [15] .
Gelatinase determination
Gelatinase activity was determined by zymography. Extracts were prepared by lysis of adipose tissues in 10 mM Phosphate buffer, pH 7.2, containing 150 mM sodium chloride, 1 % Triton X-100, 0.5% sodium deoxycholate and 0.2 % sodium azide. Total protein concentration was determined using the bicinchoninic acid method (BCA TM Protein Assay Kit assay, Pierce, Rockford, IL). Samples were analyzed on gelatin-containing gels as described [16] . 20 µg of protein was applied to non-reduced SDS-polyacrylamide gel electrophoresis using 10 % gels containing 0.1 % gelatin. Gels were renatured by exchanging SDS with Triton X-100 (2.5%) and then incubated for 24 hours at 37°C in developing buffer (50 mM Tris-HCl, pH 7.5, containing 7 mM CaCl 2 , 0.2 M NaCl, and 0.02% Brij-35). Gels were subsequently stained with Coomassie (0.5% Coomassie R250, 45% MeOH, 10% acetic acid) for 3 hours, followed by destaining (45% EtOH and 10% acetic acid). Gels were scanned (Epson Perfection V700 PHOTO scanner, Nagano, Japan) and bands quantified with NIH imageJ 1.30 software. Addition of Tolylsam (200µM) to the developing buffer totally abolished MMP-2 and MMP-9 activity (not shown).
Analysis of mRNA expression
Adipose tissues were homogenized using lysing matrix tubes (Qbiogene, Carlsbad, CA) in a Hybaid ribolyser (Thermo, Wallham, MA). Total DNA-free RNA was extracted using the RNA Easy Quiagen kit (Quiagen, Valencia, CA) and RNA concentrations were determined with the RiboGreen RNA quantification kit (Molecular Probes, Eugene, OR). Samples were aliquoted and stored at -80°C.
Reverse Transcription reactions were performed from 10 ng total RNA with thermostable RT (rTth) at 70°C for 15 min, followed by 2 min incubation at 95°C for denaturation of RNA-DNA heteroduplexes, using the GeneAmp Thermostable RNA PCR Kit (Applied Biosystems, Foster City, CA) and target specific antisense primers. Amplification was started with 15 s at 94°C, 20 s at 68°C and 10 s at 72°C (35 cycli) and terminated by 2 min at 72°C, on a GeneAmp PCR System 9700 thermocycler (Perkin Elmer, Waltham, MA). Blood was collected via the retroorbital sinus on trisodium citrate (final concentration of 0.01 M) and plasma was stored at -80°C. Intra-abdominal (gonadal, GON) and inguinal subcutaneous (SC) fat pads were removed and weighed; portions were snap-frozen in liquid nitrogen for histological and zymographic analysis, RNA or protein extraction. Other organs including kidneys, lungs, spleen, pancreas, liver and heart were also removed and weighed.
To evaluate energy expenditure, spontaneous physical activity was evaluated by placing the mice in a separate cage equipped with a turning wheel linked to a computer to register full turning cycles in a 72h period. Data are expressed as number of cycles per night (12 h), as daytime activity is very low. Body weight and food intake were monitored, and body temperature was measured using a rectal probe (TR-100, Fine Science Tools, Foster City, CA).
All animal experiments were approved by the local ethical committee (KULeuven, P06022) and were performed in accordance with the guiding principles of the American Physiological Society and the International Society on Thrombosis and Haemostasis [13] .
Histological analysis
The size and density of adipocytes were determined on 10 µm paraffin sections of SC or GON adipose tissue, stained with haematoxylin-eosin under standard conditions [5] . For each mouse at least 10 areas in 12 sections were measured using a computerized image analyzer; data are expressed as means ± SEM for the number of animals studied. Blood vessel staining was performed using the biotinylated Bandeiraea (Griffonia) Simplicifolia BSI lectin (Sigma-Aldrich, Bornem, Belgium) [14] followed by signal amplification with the Tyramide Signal Amplification Cyanine System (Perkin Elmer, Boston, MA), and analysis by computer-assisted image analysis. Blood vessel density was normalized to the adipocyte number.
Collagen was stained with Sirius red and quantified as percentage stained area per total tissue section area.
Triglyceride content in liver tissue extracts, prepared by homogenization in isopropanol, was determined with the Triglyceride FS kit (Roche Diagnostic Systems, Holzheim, Germany).
Statistical Analysis
Data are expressed as means ± SEM. Differences between groups are analyzed with the non-parametric Mann-Whitney U-test. Comparison of progress curves was performed by two-way repeated measures ANOVA. Statistical significance was set at p < 0.05.
Results
Leptin deficient (ob/ob) mice fed the HFD supplemented with Tolylsam showed lower body weight gain than control mice, resulting in significantly reduced body weight after 15 weeks (52 ± 0.8 g vs. 59 ± 1.0 g, p < 0.0001, Fig. 1 and Table 1 ). Food intake was comparable (4.0 ± 0.08 g/day vs. 3.9 ± 0.08 g/day for Expression of mRNA of MMP-2 and MMP-9 and an endogenous control gene for normalization (GAPDH or ß-actin) was measured by real-time PCR using TaqMan Gene Expression Assay products (product numbers: Mm99999915_g1 (GAPDH), Mm00607939_s1 (ß-actin), Mm00439506_m1 (MMP-2), Mm01240562_g1 (MMP-9); Applied Biosystems) on an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems), and expressed in arbitrary units (AU).
Metabolic parameters
Blood glucose concentrations were measured using Glucocard strips (Menarini Diagnostics, Firenze, Italy). Levels of triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol in plasma, as well as liver enzymes AST (aspartate aminotransferase) and ALT (alanine aminotransferase) were determined using standard laboratory assays. Insulin levels were determined using a commercially available ELISA (Mercodia, Uppsala, Sweden). controls, p= 0.6), indicating a lower feeding efficiency (weight gain normalized to caloric intake) for treated mice. Physical activity was very low in both groups (222 ± 41 turns/12h vs. 250 ± 71 turns/12h, p =0.5), and body temperature, measured at week 0, 7, and 15, did not indicate differences in thermogenesis between the two groups (35.8 ± 0.12 °C vs. 35.8 ± 0.11 °C for controls).
The fat depots were somewhat smaller in the Tolylsam treated mice, although this was only significant for the SC fat pads. A trend towards smaller adipocytes was noted in the inhibitor treated mice, but was not significant. A similar observation was made for blood vessel size, whereas the blood vessel density was significantly lower in Tolylsam treated SC and GON adipose tissues. The normalized blood vessel density, i.e. adjusted for adipocyte density, thus was lower in the Tolylsam treated mice ( Table 2 ). The weight of other organs was comparable for both groups ( Table 1 ). The liver weight was slightly enhanced in the Tolylsam treated mice, but the levels of liver enzymes were not affected (Table 3) . Furthermore, the triglyceride content in liver extracts was not significantly different in both groups (8.7 ± 0.6 µg/mg tissue for Tolylsam treated and 9.9 ± 0.2 µg/mg tissue for control samples).
Tolylsam treatment did not affect total collagen content in SC (13.5 ± 1.1 % vs. 12.7 ± 0.5 %) and in GON (8.8 ± 0.9 % vs. 9.8 ± 0.9 %) adipose tissues. Collagen structural disorganization (monitored as ratio thick/thin fibers) in Tolylsam treated and control SC (0.48 ± 0.07 vs. 0.39 ± 0.03) and GON (0.51 ± 0.11 vs. 0.57 ± 0.12) adipose tissues was also similar.
Plasma levels of glucose, insulin, total cholesterol and LDL cholesterol did not markedly differ, but triglyceride and HDL cholesterol concentrations were lower in the Tolylsam treated mice (Table 3) .
mRNA levels of MMP-2 were significantly higher upon Tolylsam treatment of the SC (732 ± 105 A.U. vs. 402 ± 50 A.U., p = 0.01), but not the GON adipose tissue (430 ± 46 A.U. vs. 490 ± 34 A.U., p = 0.3). mRNA levels of MMP-9 were also induced after treatment with Tolylsam in SC (52 ± 4 A.U. vs. 35 ± 6 A.U., p = 0.04) but not in GON (19 ± 3 A.U. vs. 15 ± 2 A.U., p = 0.5) fat tissues. On zymograms, four gelatinolytic bands were consistently observed in adipose tissue extracts, corresponding to pro-MMP-9 (92kDa), pro-MMP-2 (72 or 68 kDa, differently glycosylated) and active MMP-2 (58 kDa). Active MMP-2 (62 kDa form) and active MMP-9 (82 kDa) were not consis- inhibitor (towards MMP-1, -2, 3, -8, -9) to wild-type mice kept on HFD for 15 weeks resulted in significant reduction of adipose tissue weight [17] . The inhibitor treated adipose tissues contained significantly more collagen than controls. We have previously shown that Tolylsam (IC50 of 5nM for MMP-2, 49nM for MMP-9 and 34nM for MMP-12) at a dose of 100 mg/ kg/day significantly reduced body weight and adipose tissue mass in a nutritionally induced obesity model in wild-type mice. This was associated with significant adipocyte hypotrophy in SC and GON fat [5] . Zymography of adipose tissue extracts in the presence of Tolylsam confirmed efficient MMP-2 and MMP-9 inhibiton. Tolylsam treatment was associated with significantly reduced levels of leptin, which correlate positively with body fat mass and adipocyte size [5, 18] . Leptin contributes to enhanced MMP-2 levels in different cell types [7] [8] [9] [10] [11] [12] . In vascular smooth muscle cells leptin induces MMP-2 expression via protein kinase C-dependent activation of NAD(P)H oxidase with subsequent activation of the ERK1/2/NF-kappa B pathways [8] .
In order to establish whether MMP inhibition has the potential to impair adipose tissue development in the absence of leptin and associated reduction of MMP-2 levels, we have administered Tolylsam to leptin deficient ob/ob mice. These mice have the same genetic background (C57Bl/6) as the wild-type mice used in our previous study [5] and we have used the same dose and administration scheme of Tolylsam. We have chosen to keep these mice on a high fat diet in order to induce morbid obesity. Administration of Tolylsam was well tolerated without apparent side effects. The liver was slightly enlarged, but liver enzymes or hepatic triglyceride content were not affected by Tolylsam treatment.
Overall, treatment with Tolylsam resulted in lower body and fat pad weights after 15 weeks of HFD. This difference in SC and GON fat mass does not account for the total difference in body weight, which may be due to the fact that not all fat pads are recovered and accounted for, or to different weight of other body parts (although the weight of major organs was not affected). Given the fact that food intake, physical activity and body temperature were comparable in both groups, the feeding efficiency (weight gain per kJ energy intake) appears to be lower in the Tolylsam treated mice. It cannot be excluded that enhanced basal metabolism and/ or excretion in faeces contribute to lower body weight, as we have not been able to make a global energy baltently detected. Zymography (Fig. 2) revealed no significant difference in pro-MMP-9 levels (4.0 ± 0.2 vs. GON) . Active MMP-2 levels (58 kDa) were, however, reduced in both SC (5 ± 1 vs. 9 ± 1 %, p = 0.01) and GON (9 ± 1 vs. 13 ± 2 %, p = 0.03) inhibitor treated adipose tissues.
discussion
In adipose tissue, adipocytes are surrounded by a basement membrane that has to be extensively remodeled in order to allow the hypertrophic development of adipocytes observed in obesity. The matrix metalloproteinase (MMP) system contributes to tissue remodeling by degradation of the extracellular matrix (ECM) and basement membrane components or by activation of latent growth factors. Furthermore, MMPs play a functional role in angiogenesis and adipogenesis (reviewed in [2] ).
Several previous studies have suggested the potential to impair adipose tissue development by inhibition of MMPs. Thus, administration of galardin (100 mg/ kg/day), a hydroxamate-based broad-spectrum MMP extracts confirmed, however, lower MMP-2 activity at the level of the adipose tissue.
In conclusion, administration of Tolylsam to ob/ob mice resulted in lower body and fat pad weight. Our previous findings that MMP-2 deficient mice as well as Tolylsam treated wild-type mice also show reduced adiposity suggest a role for MMP-2 [5] . Tolylsam administration to wild-type mice resulted in reduced levels of leptin, an endocrine hormone that is secreted by adipose tissue and stimulates MMP-2 expression and activity. This study shows that the effect of Tolylsam is maintained in the absence of leptin, indicating that direct MMP inhibition by Tolylsam at the level of adipose tissue is responsible for -at least -part of its observed effect on adiposity.
ance. The decrease in plasma triglyceride levels upon Tolylsam treatment may be due to enhanced conversion into their storage form as intracellular lipid droplets, a process to which MMPs may contribute, whereas total triglyceride content in the liver was not affected.
In the SC and GON adipose tissues we observed mild adipocyte hypotrophy, without differences in adipocyte density. Blood vessel density, normalized to adipocyte density [19] , was lower in adipose tissues of Tolylsam treated mice, indicating a mild anti-angiogenic effect. It was shown previously that MMP-9, which is inhibited by Tolylsam, releases matrix-bound VEGF and thereby promotes angiogenesis [20] . In our previous study in wild-type mice with nutritionally induced obesity, we observed more marked adipocyte hypotrophy and smaller blood vessels in adipose tissues upon Tolylsam treatment [5] . It should be taken into account that under the conditions of this study (ob/ob mice deficient in leptin kept on HFD) adipocyte growth is very extreme.
Total as well as degraded collagen levels in the adipose tissues were not affected by the inhibitor treatment; however, the ratio of thick/thin collagen fibers which is below 0.5 indicates extensive collagen modification in the obese tissues.
Paradoxically, gelatinase A (MMP-2) and gelatinase B (MMP-9) mRNA expression in the adipose tissues were enhanced upon inhibitor treatment, obviously via a mechanism independent of leptin; zymography with
